Reliance Global launches LifeSci Global platform, invests in Innervate Radiopharmaceuticals targeting $250M neuroblastoma market

Reliance Global Group has launched LifeSci Global, a dedicated life sciences platform led by Scott Korman and David Turner, focusing on building and growing biotech companies. The platform's first investment is Innervate Radiopharmaceuticals, which develops PET imaging and therapies for neuroblastoma, with potential expansion into cardiovascular and neurodegenerative diseases. This move aligns with Reliance's strategy of active company-building rather than passive investing, aiming to create long-term value through expert leadership and targeted biotech innovation. LifeSci Global is now evaluating additional opportunities in the life sciences sector.